Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Table 3 Multiple regression analysis using ANS activity, age, sex, body mass index, CPZeq, BPDeq, DZPeq, and aripiprazole formulation as independent variables

Independent variable	ANS activity
	lnLF			lnHF			lnTP
	β	95%CI	p	β	95%CI	p	β	95%CI	p
Age (year)	-0.364	-0.052 to -0.018	< 0.001^a	-0.256	-0.050 to -0.008	0.007^a	-0.343	-0.050 to -0.016	< 0.001^a
Sex (reference category: female)	-0.038	-0.559 to 0.359	0.667	-0.005	-0.580 to 0.550	0.959	-0.023	-0.528 to 0.407	0.798
BMI (kg/m²)	-0.068	-0.059 to 0.026	0.444	-0.066	-0.071 to 0.033	0.477	-0.070	-0.060 to 0.026	0.435
CPZeq^b (mg/day)	-0.049	-0.001 to 0.002	0.541	-0.074	-0.002 to 0.001	0.433	-0.004	-0.001 to 0.001	0.965
BPDeq^c (mg/day)	0.071	-0.102 to 0.222	0.464	-0.064	-0.262 to 0.135	0.528	0.023	-0.145 to 0.184	0.816
DZPeq^d (mg/day)	0.058	-0.019 to 0.035	0.551	-0.010	-0.035 to 0.032	0.924	0.034	-0.023 to 0.033	0.731
Aripiprazole formulation (reference category: AOM)	-0.187	-0.952 to -0.034	0.036 ^a	0.010	-0.535 to 0.594	0.917	-0.106	-0.746 to 0.189	0.240

ANS, autonomic nervous system; AOM, aripiprazole once-monthly; BMI, body mass index; ln, natural log-transformed; HF, high-frequency; LF, low-frequency; PANSS, Positive and Negative Syndrome Scale; TP, total power; CI, confidence intervals.
^a Significant difference (p < 0.05; multiple regression analysis).
^b Daily dose of aripiprazole converted to an approximate chlorpromazine equivalent.
^c Daily dose of anticholinergic antiparkinsonian drugs converted to an approximate biperiden equivalent.
^d Daily dose of benzodiazepines converted to an approximate diazepam equivalent.

ISSN: 1471-244X